Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SHR-1314 (Vunakizumab) in Moderate-to-Severe Plaque Psoriasis
NCT03710681Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Aug 2018
- Primary completion
- Apr 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of vunakizumab in plaque psoriasis (2 cohorts), sponsored by Hengrui. Primary endpoints: Incidence and severity of Treatment-Emergent Adverse Events and Incidence of development of Anti-drug Antibodies. Status: unknown.
02
Drugs
vunakizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03710681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03710681.